Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
about
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitorsLow level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapyMonitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor.Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype.Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutationsThe pharmacogenomics of HIV therapy.HIV-1 drug resistance: can we overcome?Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.Enhancing Lay Counselor Capacity to Improve Patient Outcomes with Multimedia TechnologyIdentification of HIV inhibitors guided by free energy perturbation calculations.Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapyMasivukeni: development of a multimedia based antiretroviral therapy adherence intervention for counselors and patients in South Africa.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failedCost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma.Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.Determinants of sustained virological suppression in indigent, HIV-infected patients: is single protease inhibitor-based antiretroviral therapy truly highly active?Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay.Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlatesSociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada.Amide hydrogen exchange in HIV-1 subtype B and C proteases--insights into reduced drug susceptibility and dimer stability.A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients.Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART.
P2860
Q24554340-4C37CE30-A476-4122-9739-EF0448A162E2Q33595278-33FE9AAA-EBB0-42FF-A2C5-3B9B2C6E7B4EQ33672541-4F7C4F04-A9A7-4D9D-B416-FBD23515AE9EQ33906239-BE9CC609-5698-4493-B238-1E6A114C3823Q33971104-E990D437-60C7-41BF-A4EA-6A038022D5FAQ33971117-01701EBA-BCFB-457D-9951-56B2FA60FDA4Q33972550-5528BF4A-7FB6-4546-9973-25BF769653E9Q33979107-9134DF74-513D-4ABC-97BB-8742CF6B0923Q33981401-346F940F-97E4-45C7-93A4-D4967D6B6995Q33981706-17438B22-6E92-4AD7-B1DC-D37291C8D2C2Q34032267-CCB3C6E9-99CC-45CA-88B7-C30DFC8D5F26Q34108198-42087E5F-30DB-4156-A65C-B4BEFBE99DD5Q34331628-C24E7D63-5650-4877-ADAA-F085FBACA475Q34574033-E4BB16ED-BD31-4171-84DE-D33D3C081C3BQ34974754-25C45895-6094-4565-A0CD-0B20BDBCF932Q35120811-5010BBCA-16D3-441B-A607-4512DC05EC40Q35156231-EFB7EBE6-8C08-4A7F-A389-6F6BF7E4A74AQ35955487-54019EEF-EC1B-46FA-A2F3-3ECB49939C8FQ36708826-A9DB4848-A247-4463-8896-87F6E616733DQ36900004-A4923DCA-1E36-44E7-AAFE-9E1D0D0ADF81Q36906315-57C170F9-542E-4AC9-9026-A41079434BE1Q37018369-FF7EAF7A-7BE7-4BC9-A300-240F7270F50EQ37021823-0BE2F778-0EDC-4293-9615-04900269A99FQ38324341-D23EF3B6-D741-4612-8EB9-EE7070B83E89Q38932618-75DF9773-C101-4ADB-837C-334CE57F10D9Q39462662-E7EE305F-3C25-4A9F-9E36-EDA4E6D9A290Q39606435-8C3CA402-0E95-4A36-A679-C69380A46B5DQ39626204-467E18E9-8696-498F-97FB-8BC05B966375Q39689549-45C75C59-FFAA-4F82-A7CF-D2AB641CB5CCQ39989338-C0C80B60-45AE-4B88-9B73-9574AAFE5ABEQ41902281-21F55C2E-4600-41F3-AECD-8353FE251BC4Q41932161-13CB1CDF-8482-42F8-8BE1-A4D6AB3996E8Q42184665-8BB9E8B5-3C4A-4FDD-9531-69C2E0E5770DQ43759278-20FB53F1-7171-4F79-AA44-6A918E24E990Q43822039-4DEA9F5F-F0D4-4F8D-9D0A-75BB57B0E2C9Q44062987-1F517A74-A925-4E7A-93BF-276645F72E80Q44224686-CB2B978C-5E2E-4731-8236-E2C9723D7255Q44606303-83EBC397-408B-4D7A-A7ED-3A8DC11FE26EQ54003890-140CE856-7002-4BAF-ACA5-F3845FB5A824
P2860
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Baseline HIV drug resistance p ...... herapy in a community setting.
@en
Baseline HIV drug resistance p ...... herapy in a community setting.
@nl
type
label
Baseline HIV drug resistance p ...... herapy in a community setting.
@en
Baseline HIV drug resistance p ...... herapy in a community setting.
@nl
prefLabel
Baseline HIV drug resistance p ...... herapy in a community setting.
@en
Baseline HIV drug resistance p ...... herapy in a community setting.
@nl
P2093
P1433
P1476
Baseline HIV drug resistance p ...... herapy in a community setting.
@en
P2093
Alexander C
Harrigan PR
Montaner JS
Verbiest W
P304
P356
10.1097/00002030-199910010-00008
P407
P577
1999-10-01T00:00:00Z